PriceTargets.com logo

OncoCyte - OCX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $3.90
  • Forecasted Upside: 56.00%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.50 As of 04/19/2024 01:00 AM ET
▼ -0.06 (-2.34%)

This chart shows the closing price for OCX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OncoCyte Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OCX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OCX

Analyst Price Target is $3.90
▲ +56.00% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for OncoCyte in the last 3 months. The average price target is $3.90, with a high forecast of $5.00 and a low forecast of $3.00. The average price target represents a 56.00% upside from the last price of $2.50.

This chart shows the closing price for OCX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 polled investment analysts is to moderate buy stock in OncoCyte. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2024StephensReiterated RatingEqual Weight ➝ Equal Weight$4.00Low
4/15/2024BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$5.00Low
11/13/2023Piper SandlerLower TargetNeutral ➝ Neutral$3.50 ➝ $3.00Low
11/9/2023Needham & Company LLCLower TargetBuy ➝ Buy$4.25 ➝ $3.60Low
8/24/2023BenchmarkLower TargetSpeculative Buy ➝ Speculative Buy$9.00 ➝ $5.00Low
8/10/2023Needham & Company LLCLower TargetBuy ➝ Buy$9.00 ➝ $4.25Low
4/4/2023Needham & Company LLCLower TargetBuy$28.00 ➝ $9.00Low
12/1/2022Lake Street CapitalDowngradeBuy ➝ Hold$60.00 ➝ $10.00Low
11/17/2022BenchmarkLower Target$60.00Low
11/17/2022Piper SandlerDowngradeOverweight ➝ Neutral$20.00 ➝ $10.00Low
11/14/2022Piper SandlerLower TargetOverweight ➝ Overweight$30.00 ➝ $20.00Low
11/11/2022Needham & Company LLCLower TargetBuy$42.00 ➝ $28.00Low
8/17/2022Piper SandlerBoost TargetOverweight$28.00 ➝ $30.00N/A
8/11/2022Lake Street CapitalLower TargetBuy$120.00 ➝ $60.00N/A
8/11/2022Needham & Company LLCLower TargetBuy$45.00 ➝ $42.00N/A
5/24/2022StephensDowngradeOverweight ➝ Equal WeightN/A
5/15/2022Piper SandlerLower Target$36.00 ➝ $28.00N/A
3/17/2022Piper SandlerLower TargetOverweight$62.00 ➝ $36.00N/A
3/11/2022Lake Street CapitalLower TargetBuy$220.00 ➝ $120.00N/A
3/11/2022Needham & Company LLCLower TargetBuy$100.00 ➝ $80.00N/A
1/7/2022StephensInitiated CoverageOverweight$62.00N/A
12/17/2021BTIG ResearchReiterated RatingBuy$100.00N/A
12/16/2021Needham & Company LLCLower TargetBuy$140.00 ➝ $100.00N/A
11/10/2021Needham & Company LLCLower TargetBuy$160.00 ➝ $140.00N/A
10/13/2021Needham & Company LLCReiterated RatingBuy$160.00N/A
6/16/2021Needham & Company LLCReiterated RatingBuy$160.00N/A
3/17/2021Needham & Company LLCReiterated RatingBuy$160.00N/A
3/17/2021BenchmarkBoost TargetBuy$120.00 ➝ $220.00N/A
2/10/2021Piper SandlerBoost Target$80.00 ➝ $140.00N/A
1/7/2021BenchmarkUpgradeSpeculative Buy ➝ Buy$120.00N/A
12/16/2020Piper SandlerUpgradeOverweight$40.00 ➝ $80.00High
11/30/2020BTIG ResearchInitiated CoverageBuy$100.00High
11/13/2020Piper SandlerBoost TargetNeutral$30.00 ➝ $40.00Medium
11/13/2020Needham & Company LLCBoost TargetBuy$40.00 ➝ $80.00N/A
11/10/2020KeyCorpInitiated CoverageOverweight$100.00Medium
11/9/2020KeyCorpInitiated CoverageOverweight$100.00N/A
10/21/2020Needham & Company LLCReiterated RatingBuy$40.00N/A
10/2/2020Needham & Company LLCReiterated RatingBuy$40.00N/A
7/30/2020BenchmarkLower TargetSpeculative Buy$140.00 ➝ $120.00N/A
6/30/2020Chardan CapitalDowngradeBuy ➝ NeutralHigh
6/30/2020Needham & Company LLCInitiated CoverageBuy$80.00N/A
6/30/2020Piper SandlerDowngradeOverweight ➝ NeutralN/A
6/30/2020Lake Street CapitalLower TargetBuy$120.00 ➝ $80.00N/A
6/25/2020Piper SandlerBoost TargetOverweight$108.00 ➝ $150.00N/A
6/17/2020Needham & Company LLCReiterated RatingBuy$80.00N/A
6/2/2020Needham & Company LLCInitiated CoverageBuy$80.00N/A
5/13/2020Chardan CapitalReiterated RatingBuy$155.00N/A
3/26/2020Chardan CapitalReiterated RatingBuy$155.00N/A
11/15/2019Chardan CapitalReiterated RatingBuy$155.00N/A
7/3/2019BenchmarkReiterated RatingBuyN/A
6/7/2019BenchmarkSet TargetBuy$140.00N/A
5/17/2019Chardan CapitalSet TargetBuy$160.00N/A
4/25/2019Chardan CapitalReiterated RatingBuy$155.00N/A
(Data available from 4/20/2019 forward)

News Sentiment Rating

0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/23/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2024
  • 1 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
4/20/2024

Current Sentiment

  • 1 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

OncoCyte logo
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Read More

Today's Range

Now: $2.50
Low: $2.49
High: $2.55

50 Day Range

MA: $2.93
Low: $2.50
High: $3.07

52 Week Range

Now: $2.50
Low: $2.08
High: $6.20

Volume

53,925 shs

Average Volume

148,104 shs

Market Capitalization

$20.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of OncoCyte?

The following Wall Street sell-side analysts have issued stock ratings on OncoCyte in the last year: Benchmark Co., Needham & Company LLC, Piper Sandler, Stephens, and StockNews.com.
View the latest analyst ratings for OCX.

What is the current price target for OncoCyte?

4 Wall Street analysts have set twelve-month price targets for OncoCyte in the last year. Their average twelve-month price target is $3.90, suggesting a possible upside of 56.0%. Benchmark Co. has the highest price target set, predicting OCX will reach $5.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $3.00 for OncoCyte in the next year.
View the latest price targets for OCX.

What is the current consensus analyst rating for OncoCyte?

OncoCyte currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for OCX.

What other companies compete with OncoCyte?

Other companies that are similar to OncoCyte include Cardio Diagnostics, Trinity Biotech, Achilles Therapeutics, Biomerica and ImmuCell. Learn More about companies similar to OncoCyte.

How do I contact OncoCyte's investor relations team?

OncoCyte's physical mailing address is 15 CUSHING, IRVINE CA, 92618. The company's listed phone number is (949) 409-7600 and its investor relations email address is [email protected]. The official website for OncoCyte is oncocyte.com. Learn More about contacing OncoCyte investor relations.